新型支气管内给药导管向猪气道壁递送紫杉醇的药代动力学与安全性
该研究在健康猪模型中经微型针灌注导管向支气管壁注射紫杉醇(PTX),评估局部组织病理及血浆和组织药物浓度。结果显示至1.5 mg/mL剂量仅引起轻微组织损伤,2.5 mg/mL出现剂量限制性组织反应;血浆PTX仅可检测至5天,而支气管组织浓度在7天和28天时仍高于10 nmol/L的治疗水平,且外周组织未检出药物。
要点
- 经支气管壁注射紫杉醇至1.5 mg/mL仅引起轻微组织损伤,2.5 mg/mL出现剂量限制性反应。
- 血浆紫杉醇仅可检测至5天,AUC(0-5d)较已批准静脉剂量的AUC(0-∞) 6300 ng h/mL低20至50倍。
- 注射后7天和28天支气管组织紫杉醇浓度仍高于10 nmol/L的肿瘤治疗水平,外周组织未检出。
核心结论
- 经支气管壁直接注射紫杉醇安全可行,局部组织浓度在随访期内维持治疗水平。
研究设计与样本
- 在健康猪中经微型针灌注导管行支气管壁注射,评估局部组织病理及血浆和组织紫杉醇浓度。
主要发现
- 通用紫杉醇至1.5 mg/mL仅引起轻微组织损伤,2.5 mg/mL出现剂量限制性组织反应。
- 血浆紫杉醇可检测至5天但28天不可测,AUC(0-5d)较已批准静脉剂量AUC(0-∞) 6300 ng h/mL低20至50倍。
- 注射后7天和28天支气管组织紫杉醇浓度高于10 nmol/L,外周组织未检出。
- Abraxane与通用紫杉醇结果相似。
关键数值与推荐
- 通用紫杉醇注射浓度包括0.05、0.5、1.5或2.5 mg/mL,共102次注射。
- 生理盐水14次注射,Abraxane 0.5 mg/mL共24次注射。
- 评估时间点为注射后7、20或28天。
临床怎么用
- 支持经支气管内导管向气道壁局部递送紫杉醇的可行性,但需进一步临床研究验证。
局限性
- 研究在健康猪中进行,非肿瘤模型,结果外推至人类需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Intratumoral administration of chemotherapeutic agents is a treatment modality that has proven efficacious in reducing the recurrence of tumours and increases specificity of treatment while minimizing systemic side effects. Direct intratumoral injection of malignant airway obstruction has potential therapeutic benefits but tissue drug concentrations and side-effect profiles are poorly understood. METHODS: Bronchial wall injection of generic paclitaxel (PTX) (102 injections of 0.05, 0.5, 1.5 or 2.5 mg/mL in 10 healthy pigs), saline (14 injections in 2 healthy pigs) or Abraxane (ABX) (24 injections of 0.5 mg/mL in 4 healthy pigs) was performed with a microneedle infusion catheter. Local histopathology, plasma and tissue PTX concentrations were evaluated at 7, 20 or 28 days post-injection. RESULTS: Injection of generic PTX directly into the bronchial wall at doses up to 1.5 mg/mL only caused minimal tissue injury. Dose-limiting tissue reaction was observed at 2.5 mg/mL. Plasma PTX was detectable for up to 5 days but not at 28 days, with area under the curve (AUC)(0-5d) 20- to 50-fold lower than the AUC(0-∞) of 6300 ng h/mL for the approved intravenous dose. At 7 and 28 days post-injection, bronchial PTX tissue concentrations were above a 10-nmol/L cancer therapeutic level. PTX was not found in peripheral tissues. Similar results were observed between ABX and generic PTX. CONCLUSION: Results of these studies confirm the administration of PTX directly into the bronchial wall is safe and feasible. PTX was detectable in plasma for <7 days but tissue concentrations remained therapeutic throughout the follow-up period.
引用
- Tsukada H, Entcheva-Dimitrov P, Ernst A, et al. Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter. Respirology. 2017. PMID: 29139187. doi:10.1111/resp.13214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。